Type 2 Diabetes

Data from more than 1500 general practices are providing a comprehensive overview of the impact of obesity on risk of severe COVID-19 outcomes in England—suggesting each BMI increase beyond 23 kg/m2 increased risk of hospital admission and death.

New information from a phase 3 trial used as part of the FDA approval is providing insight into the safety and efficacy of dasiglucagon for treatment of severe hypoglycemia in adult patients with type 1 diabetes.

The majority of patients with a treatment gap longer than 12 weeks had worsening visual acuity, notes a new ARVO study.

The SGLT-2 inhibitor, generally used for cardiometabolic and cardiovascular risk reduction, may provide similar benefits for the ophthalmic disease.

An expert discusses his interest in a pair of macular degeneration and diabetic macular edema treatments that may provide less burden and consistent efficacy in patients.

A new CDC study shows the link between poor vision and heart disease is not just limited to cardiovascular events.

Allen Ho, MD, discusses the Protocol W outcomes and what they indicate for prescribing ophthalmologists.

The rates of both diseases have been increasingly linked in recent years.

A study from McMaster University is providing updated information related to the prevalence of hypertension and albuminuria in younger patients with type 2 diabetes.

A cohort analysis of African American patients finds an association between 1-year ozone concentrations and diagnosed incident diabetes at clinical visit.

New data show a link between body mass index and increased risk of adverse effects from COVID-19.

A systematic review and meta-analysis of data from nearly 2 dozen studies is providing new insight into the phenotypes of patients with diabetes associated with worse outcomes from COVID-19.

New data show that youths with type 1 diabetes perceive their sleep as disrupted, but investigators find similar objective outcomes in youths without diabetes.

Men, individuals with 15 years of type 2 diabetes, and those older than 55 years old had the greatest absolute risk reduction.

New data find significant associations between every five-year earlier onset of diabetes and a higher hazard rate of dementia, in patients aged 35-75 years old.

A retrospective analysis of matched cohorts has led investigators to suggest bariatric surgery should be viewed as a first-line treatment for the management of obesity in patients with type 2 diabetes.

April's month in review features stories related to new diabetes medications, stem cells, disparities in care of women, and how exposure to endocrine-disrupting chemicals in pregnancy can impact mental health following delivery. Check back in during the last weekend of each month for the next Endocrine Month in Review.

Anti-VEGF administration did increase the risk of nonocular hemorrhages, mostly in patients with AMD.

TIMI Group investigators found the effects of dapagliflozin on cardiovascular risk in patients with diabetes were comparable in those with markers of CKD and those without markers of CKD at baseline.

Using data from nearly 1 million patients with type 2 diabetes in a commercial database, investigators provide a comprehensive of the impact race/ethnicity, gender, and income can have on the likelihood of receiving a prescription for SGLT2 inhibitors.

An analysis of the DECLARE-TIMI 58 trial indicates the cardiovascular benefit of dapagliflozin use in patients with diabetes was consistent regardless of baseline kidney function and suggests the effects could be independent of glucose reduction.

A new study on dapagliflozin use finds consistent risk reduction in treatment of patients with higher rates of kidney dysfunction.

A trial led by clinicians from Northwestern Medicine suggests the presence of ischemic leg symptoms could serve as a useful indicator for patients to help determine whether they will see a meaningful benefit from their walking program.

An analysis of the CLARIFY registry is providing clinicians with further insight into the impact of diabetes in patients with chronic coronary syndromes, particularly the increased risk of stroke, myocardial infarction, and cardiovascular death.

New data suggest injections of adipose-derived SVF cells could elicit wound closure in patients with nonhealing diabetic foot ulcers and, subsequently, reduce the need for amputation in this patient population.